Fig. 3

Vasculotide (VT) therapy decreased pulmonary hyperpermeability in Streptococcus pneumoniae-infected mice. S. pneumoniae-infected mice (5 × 10⁶ colony-forming units/mouse) were intravenously (i.v.) treated with VT (100, 200, or 500 ng) or PBS 22 h, 34 h, and 46 h postinfection (p.i.). Lung preparation and bronchoalveolar lavage were performed 24 h or 48 h p.i. Human serum albumin (HSA) was i.v. administered 23 h or 47 h p.i., and HSA bronchoalveolar lavage fluid (BALF)/plasma ratio was determined by enzyme-linked immunosorbent assay to quantify permeability. At a dose of 500 ng, VT significantly reduced lung hyperpermeability 24 h (a) and 48 h (b) p.i. compared with the PBS-treated controls. Values are given as mean + SEM (n = 5–7). *p < 0.05, **p < 0.01 between indicated groups